Stem cell transplantation holds great promise as a therapeutic strategy in human genetic disorders, including muscular dystrophies. This proposal aims at understanding and addressing three major hurdles of cell-based therapeutic approaches to Duchenne muscular dystrophy: Stem cell isolation, propagation and engraftment. The proposal is based on the recent characterization of the novel ATP-binding cassette transporter ABCB5 P-glycoprotein by the applicant, which marks stem cell phenotype-expressing cell subsets in muscle and skin, and regulates as a determinant of membrane potential progenitor cell fusion and resultant differentiation. Preliminary studies indicate a myogenic potential of ABCB5 progenitors in vitro.
The Specific Aims of this study are 1. To define the myogenic potential of ABCBS-positive progenitors derived from muscle or skin vis-a-vis ABCBS-negative cell populations, and to dissect the role of ABCB5 in regulating myoprogenitor fusion into multinucleated myotubes using ABCB5-specific cell differentiation and fusion assays in vitro. 2. To identify the molecular regulatory networks associated with the ABCBS-positive progenitor phenotype and to determine whether such networks can be specifically modulated to induce in vitro myoprogenitor propagation. 3. To investigate the capacity of xeno- or allografted ABCBS-positive myoprogenitors isolated from human or murine muscle or skin to restore dystrophin expression in an immunodeficient mouse model of DMD (NOD/Rag1nullDMDmdx5cv) in vivo, and define the role of ABCB5 in donor cell fusion into recipient myofibers, and hence in donor cell engraftment and stem cell therapeutic efficacy. Thus, the proposal is highly relevant to efforts directed at developing novel therapeutic approaches to Duchenne muscular dystrophy and other inherited myopathies. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08NS051349-02
Application #
7151464
Study Section
NST-2 Subcommittee (NST)
Program Officer
Porter, John D
Project Start
2006-01-01
Project End
2010-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
2
Fiscal Year
2007
Total Cost
$133,920
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Ksander, Bruce R; Kolovou, Paraskevi E; Wilson, Brian J et al. (2014) ABCB5 is a limbal stem cell gene required for corneal development and repair. Nature 511:353-7
Wilson, Brian J; Schatton, Tobias; Frank, Markus H et al. (2011) Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. Curr Colorectal Cancer Rep 7:128-135
Frank, Natasha Y; Schatton, Tobias; Kim, Soo et al. (2011) VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 71:1474-85
Frank, Natasha Y; Schatton, Tobias; Frank, Markus H (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 120:41-50
Schatton, Tobias; Schütte, Ute; Frank, Natasha Y et al. (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 70:697-708
Izawa, Atsushi; Schatton, Tobias; Frank, Natasha Y et al. (2010) A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun 394:646-52
Ma, Jie; Lin, Jennifer Y; Alloo, Allireza et al. (2010) Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402:711-7
Schatton, Tobias; Frank, Natasha Y; Frank, Markus H (2009) Identification and targeting of cancer stem cells. Bioessays 31:1038-49
Frank, Natasha Y; Kho, Alvin T; Schatton, Tobias et al. (2006) Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. J Cell Biol 175:99-110